MOH Trails Peers Into Q3 Print as Options Revert

Molina Healthcare gained 0.9% over the past week against a peer median of roughly 1.9%, with CNC up 1.5%, ELV up 2.7%, and UNH up 4.2%, making Molina the laggard in its managed-care group even as short interest remains the most elevated of the cohort at 5.6% of free float.

The options picture has shifted materially since the bullish repositioning documented in prior coverage. The put/call ratio recovered to 0.84 on October 23, still below its 20-day average of 1.12 but no longer at the extreme low of 0.77 that characterised earlier in the week. The z-score has moved back toward neutral at minus 1.6 standard deviations, compared with the minus 2.5 reading from October 22. Short interest itself has barely moved: 2.86 million shares short, essentially flat on the week and down about 7.6% over the past month. The borrow market remains completely uncontested. Availability is 9,071% of shares currently shorted, meaning the lending pool carries roughly 90 shares available for every one borrowed, with cost to borrow at 0.45%.

Where the analyst community lands is the live question. On October 23, UBS raised its target to $225 from $202 while keeping a Neutral rating; Morgan Stanley lifted its target to $192 from $167 also at Equal-Weight; RBC Capital nudged to $222 from $218 at Sector Perform. Barclays moved the other way, trimming to $178 from $180 at Underweight. The mean target is $219, a slim 4.8% above the current price of $209.15, and the consensus skews toward hold-equivalent ratings with Barclays the clearest bearish voice. The bull case rests on Molina's 2029 framework targeting $64 billion in premium revenue, AI-driven cost savings of 100 to 150 basis points, and structural share-gain potential in the Duals segment where Molina holds only 6% penetration against 16% Medicaid share. Against that, bears point to Marketplace weakness, a 2026 Medicaid rate environment modelled at 4% against roughly 5% cost trend, and OBBBA-related membership attrition that management has flagged could exceed 6%. The embedded earnings backlog has already been revised down from above $11 per share at the May investor day to $9.

One ownership move is worth noting. BlackRock disclosed an 11.7% stake in its April filing, up from 6.9% previously, and institutional data through September shows the position has grown further to 12.6% of shares. That is the single largest holder by a wide margin, adding a degree of passive and active anchor support that the short interest level alone does not reflect. On the other side, T. Rowe Price has cut its disclosed stake from 6.5% to 1.9% since early 2025, and Capital World Investors trimmed from 6.8% to 4.9%, each falling below the 5% threshold. As always, stakes below 5% may exit without a further filing.

Wednesday's print will test whether Molina's Medicaid medical cost ratio is improving enough to justify an analyst community that has lifted targets in the days before the number but stopped short of upgrading its rating.